Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy - Full Text View

Sponsor:	Northwestern University
Information provided by:	Northwestern University
ClinicalTrials.gov Identifier:	NCT01313117

Purpose

This study is being done because peripheral neuropathy, a condition that interrupts sensation in your limbs, is a common side effect of paclitaxel. There is some evidence that alpha lipoic acid (ALA), an antioxidant compound, protects neurons after exposure to paclitaxel. The purpose of this study is to assess the safety and tolerability of ALA and to find the best dose of ALA in patients that receive chemotherapy.

Condition	Intervention	Phase
Peripheral Neuropathy	Dietary Supplement: Alpha lipoic acid	Phase 1 Phase 2

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Dose Finding and Tolerability Study of Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Peripheral Neuropathy

Resource links provided by NLM:

Genetics Home Reference related topics: Charcot-Marie-Tooth disease

MedlinePlus related topics: Peripheral Nerve Disorders

Drug Information available for: Paclitaxel

U.S. FDA Resources

Further study details as provided by Northwestern University:

Primary Outcome Measures:

Identification of the optimal dose of ALA [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]
based on acceptable adverse event (AE) profile

Secondary Outcome Measures:

Proportion of patients who complete the proposed regimen of daily ALA [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Cumulative rate of adverse events [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
Total neuropathy score (TNS) [ Time Frame: 4 months ] [ Designated as safety issue: No ]

Estimated Enrollment:	30
Study Start Date:	July 2011
Estimated Study Completion Date:	July 2012
Estimated Primary Completion Date:	July 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Alpha lipoic acid Oral administration three times daily (morning, mid-day, night)	Dietary Supplement: Alpha lipoic acid The baseline dose is 100 mg three times daily for four months. Dose escalation will occur until a maximum tolerated dose is found. Other Name: Thioctic Acid

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Diagnosis of Breast cancer.
Breast cancer must meet the following criteria:
- Early stage breast cancer (stages I, IIA) must be estrogen receptor (ER) positive AND low tumor grade (histopathologic grade 1 or 2)
- Locally advanced breast cancer (LABC) (stages IIB, IIIA, IIB as defined by the Union for International Cancer Control and American Joint Committee on Cancer) must be ER positive, HER2 positive or HER2 negative, AND satisfy the following requirements: high endocrine responsiveness (defined as greater than 50% of tumor cells staining for hormone receptors), Grade 1 or 2 histological grade, less than 4 nodes positive, absence of extensive peritumoral vascular invasion, AND pathological tumor size less than 5 cm.
- Inflammatory breast cancer (IBC) (stage IIIC)
- Metastatic breast cancer (stage IV)
Must be receiving single agent paclitaxel in their prescribed chemotherapy regimen.
Age > 18 years. There is no upper age limit for participation in this study.
Required lab values: AST, ALT, creatinine
Women of childbearing potential and sexually active males must agree to use contraception while on study.
ECOG performance status 0,1,2
All patients must have given signed, informed consent.

Exclusion Criteria

Breast cancer meeting the following criteria:
- Breast cancer stage 0
- Early stage breast cancer (stages I, IIA) that is ER negative OR higher tumor grade (histopathologic grade greater than 2)
- Stages I, II, and IIIA triple negative breast cancer (negative for estrogen receptors, progesterone receptors, and HER2)
- LABC (stages IIB, IIIA, IIB) if they have low endocrine responsiveness (defined as less than 50% of tumor cells staining for hormone receptors), Grade 3 histological grade, 4 or more nodes positive, presence of extensive peritumoral vascular invasion, OR pathological tumor size greater than 5 cm
- LABC (stages IIB, IIIA, IIB) that are ER negative
Evidence of pre-existing peripheral neuropathy as determined by baseline Michigan neuropathy screening instrument score > 2.
Previous chemotherapy treatment of any kind.
AST and ALT >2 times upper limit of normal; Creatinine > 2.0 mg/dL.
Current use of medications or substances known to be associated with peripheral neuropathy.
Use of ALA or other anti-oxidant supplements during the prior three months.
Diabetes mellitus or use of medications known to lower blood sugar.
Participation in any other experimental trial.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01313117

Contacts

Contact: Emily C. Kunka, CCRP	312-503-0160	nwu-eck116@northwestern.edu
Contact: Patricia Casey, OTR	312-695-0774	pcasey1@nmff.org

Locations

United States, Illinois
Northwestern Medical Faculty Foundation	Not yet recruiting
Chicago, Illinois, United States, 60611
Contact: Emily C. Kunka, CCRP 312-503-0160 nwu-eck116@northwestern.edu
Principal Investigator: Jeffrey A. Allen, MD
Sub-Investigator: Robert Sufit, MD
Sub-Investigator: Jeffrey Raizer, MD
Sub-Investigator: Judith Paice, PhD
Sub-Investigator: Julian Schink, MD
Sub-Investigator: William Gradishar, MD

Sponsors and Collaborators

Northwestern University

Investigators

Principal Investigator:

Jeffrey A. Allen, MD

Northwestern University

More Information

Additional Information:

Northwestern University Neuromuscular Disorders Program This link exits the ClinicalTrials.gov site

Publications:

Siau C, Xiao W, Bennett GJ. Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol. 2006 Oct;201(2):507-14. Epub 2006 Jun 22.

McCarty MF, Barroso-Aranda J, Contreras F. The "rejuvenatory" impact of lipoic acid on mitochondrial function in aging rats may reflect induction and activation of PPAR-gamma coactivator-1alpha. Med Hypotheses. 2009 Jan;72(1):29-33. Epub 2008 Sep 11. Review.

Melli G, Taiana M, Camozzi F, Triolo D, Podini P, Quattrini A, Taroni F, Lauria G. Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy. Exp Neurol. 2008 Dec;214(2):276-84. Epub 2008 Sep 9.

Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006 Nov;29(11):2365-70.

Cremer DR, Rabeler R, Roberts A, Lynch B. Safety evaluation of alpha-lipoic acid (ALA). Regul Toxicol Pharmacol. 2006 Oct;46(1):29-41. Epub 2006 Aug 14.

Segermann J, Hotze A, Ulrich H, Rao GS. Effect of alpha-lipoic acid on the peripheral conversion of thyroxine to triiodothyronine and on serum lipid-, protein- and glucose levels. Arzneimittelforschung. 1991 Dec;41(12):1294-8.

GAL EM, RAZEVSKA DE. Studies on the in vivo metabolism of lipoic acid. 1. The fate of DL-lipoic acid-S35 in normal and thiamine-deficient rats. Arch Biochem Biophys. 1960 Aug;89:253-61. No abstract available.

Cremer DR, Rabeler R, Roberts A, Lynch B. Long-term safety of alpha-lipoic acid (ALA) consumption: A 2-year study. Regul Toxicol Pharmacol. 2006 Dec;46(3):193-201. Epub 2006 Aug 8.

Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schutte K, Gries FA. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995 Dec;38(12):1425-33.

Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Moller W, Tritschler HJ, Mehnert H. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res. 1999 Sep;31(3):171-9.

Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schutte K, Kerum G, Malessa R. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999 Aug;22(8):1296-301.

Ruhnau KJ, Meissner HP, Finn JR, Reljanovic M, Lobisch M, Schutte K, Nehrdich D, Tritschler HJ, Mehnert H, Ziegler D. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999 Dec;16(12):1040-3.

Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O'Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D; SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003 Mar;26(3):770-6. Erratum in: Diabetes Care. 2003 Jul;26(7):2227.

Responsible Party:	Jeffrey A. Allen, MD; Assistant Professor of Neurology, Northwestern University
ClinicalTrials.gov Identifier:	NCT01313117 History of Changes
Other Study ID Numbers:	NUALA-01, STU00041525
Study First Received:	March 9, 2011
Last Updated:	June 14, 2011
Health Authority:	United States: Food and Drug Administration

Keywords provided by Northwestern University:

chemotherapy
peripheral neuropathy
paclitaxel
breast cancer

Additional relevant MeSH terms:

Peripheral Nervous System Diseases
Demyelinating Diseases
Polyneuropathies
Nerve Compression Syndromes
Neurologic Manifestations
Neurotoxicity Syndromes
Neuromuscular Diseases
Nervous System Diseases
Signs and Symptoms
Poisoning
Substance-Related Disorders
Thioctic Acid
Paclitaxel
Antioxidants

Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protective Agents
Physiological Effects of Drugs
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 23, 2012